loading page

Transcatheter mitral valve repair using the Cardioband® system: Histopathological insights in device ingrowth and biocompatibility
  • +3
  • Martin Schmiady,
  • Mathias van Hemelrijck,
  • Maurizio Taramasso,
  • Juri Sromicki,
  • Carlos Mestres,
  • Matthias Sigler
Martin Schmiady
UniversitatsSpital Zurich
Author Profile
Mathias van Hemelrijck
UniversitatsSpital Zurich
Author Profile
Maurizio Taramasso
Hirslanden Klinik Hirslanden
Author Profile
Juri Sromicki
UniversitatsSpital Zurich
Author Profile
Carlos Mestres
University Hospital Zurich
Author Profile
Matthias Sigler
Georg -August University,
Author Profile

Abstract

Surgical implantation of a complete or incomplete ring to reduce the valve annulus and improve leaflet coaptation is the mainstay of mitral valve surgery. The Cardioband® system (Edwards Lifesciences, Irvine, CA, USA) was designed to address the pathophysiological mechanism of annular dilatation through a catheter-based approach. We present the histopathological workup of a Cardioband® device, which had been implanted 21 months earlier in a 34-year-old male with ischemic cardiomyopathy. Device examination demonstrate a well-positioned and securely anchored device. The described tissue reactions may have an impact on choice of device and timing in case of re-do surgery.

Peer review status:ACCEPTED

13 Jun 2021Submitted to Journal of Cardiac Surgery
19 Jun 2021Assigned to Editor
19 Jun 2021Submission Checks Completed
22 Jun 2021Review(s) Completed, Editorial Evaluation Pending
23 Jun 2021Editorial Decision: Accept